Anteris Technologies Ltd (ASX: AVR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Anteris Technologies Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $58.88 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 6.94 million
Earnings per share -2.583
Dividend per share N/A
Year To Date Return 117.33%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

Anteris Technologies Ltd (ASX: AVR)
Latest News

AVR ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Anteris Technologies Ltd

Formerly known as Admedus Ltd (ASX: AHZ), Anteris Technologies Ltd (ASX: AVR) is a healthcare company specialising in the design and production of heart valve and tissue products.

After having sold the rights to its CardioCel® and VascuCel® patch products in 2019, the company’s main focus today is on its Adapt® BioScaffold products and the development of new heart valve replacement solutions. According to Anteris, the Adapt products are used across more than 135 medical centres globally.

In 2020, the company commenced human trials of its DurAVR™ heart valve.

The Anteris share price has been a highly disappointing performer on the ASX, losing more than 90% of its value over the past five years. The company has executed several capital raisings and has struggled with debt and cash flow issues.

AVR Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
22 Jul 2021 $8.49 $0.18 2.17% 14,840 $8.31 $8.55 $8.16
21 Jul 2021 $8.31 $0.16 1.96% 30,739 $8.16 $8.31 $7.71
20 Jul 2021 $8.15 $-0.26 -3.09% 13,786 $8.55 $8.55 $8.15
19 Jul 2021 $8.41 $-0.02 -0.24% 18,762 $8.44 $8.52 $8.41
16 Jul 2021 $8.43 $0.12 1.44% 30,100 $8.48 $8.53 $8.31
15 Jul 2021 $8.31 $0.21 2.59% 30,274 $8.10 $8.53 $8.01
14 Jul 2021 $8.10 $-0.20 -2.41% 7,168 $8.00 $8.30 $7.95
13 Jul 2021 $8.30 $0.20 2.47% 7,280 $8.15 $8.30 $8.10
12 Jul 2021 $8.10 $0.25 3.18% 28,483 $7.90 $8.10 $7.66
09 Jul 2021 $7.85 $0.25 3.29% 32,937 $7.78 $7.85 $7.45
08 Jul 2021 $7.60 $-0.10 -1.30% 29,075 $7.66 $7.71 $7.43
07 Jul 2021 $7.70 $0.14 1.85% 50,922 $7.50 $7.70 $7.35
06 Jul 2021 $7.56 $0.15 2.02% 14,258 $7.70 $7.70 $7.21
05 Jul 2021 $7.41 $0.21 2.92% 8,061 $7.29 $7.50 $7.20
02 Jul 2021 $7.20 $0.17 2.42% 5,269 $7.16 $7.29 $7.06
01 Jul 2021 $7.03 $0.23 3.38% 2,658 $7.00 $7.07 $7.00
30 Jun 2021 $6.80 $-0.10 -1.45% 31,933 $6.96 $7.30 $6.80
29 Jun 2021 $6.90 $-0.12 -1.71% 7,021 $7.02 $7.10 $6.90
28 Jun 2021 $7.02 $-0.04 -0.57% 17,720 $7.05 $7.18 $6.88
25 Jun 2021 $7.06 $-0.19 -2.62% 14,083 $7.25 $7.26 $7.06
24 Jun 2021 $7.25 $-0.11 -1.49% 2,837 $7.38 $7.38 $7.25
23 Jun 2021 $7.36 $0.31 4.40% 5,971 $7.05 $7.55 $7.05

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
07 Jun 2021 Stephen (Steve) Denaro Buy 5 $40,047
On-market trade.
10 Dec 2020 John Seaberg Expiry 1 $3,800
Options expired.
10 Dec 2020 Wayne Paterson Expiry 1 $3,800
Options expired.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Stephen (Steve) Denaro Company SecretaryNon-Executive Director Oct 2018
Mr Denaro has more than 30 years of senior level and Board level experience across publicly-listed companies, serving as Chief Financial Officer, Company Secretary and Director. He brings experience in managing compliance with finance and accounting regulatory requirements. He has had manage investment acquisitions and subsequent funding (domestic and international). Mr Denaro has a interest in start-up companies. He is also a Non-Executive Director and Chair of the Audit & Risk Committee of a not-for-profit company, National Affordable Housing Consortium Limited. He is Chair of the Risk Management Committee.
Mr John Seaberg Non-Executive DirectorNon-Executive Chairman Oct 2014
Mr Seaberg has experience in cardiovascular products and markets. From 2008 until its sale to Baxter in 2012, Mr Seaberg served as Chairman of the Board of Synovis Inc. From 2007 until 2014 he was Founder, Chairman and CEO of NeoChord Inc. From 1996 to 2006, Mr Seaberg served at Guidant Corp where he served in range of executive level positions including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Management. In 1991, Mr Seaberg co-founded ACIST Medical and served as its first President and CEO. He was also the founder and CEO of Seaberg Medical. He is a member of the Risk Management Committee.
Mr Wayne Paterson Managing DirectorChief Executive Officer Feb 2016
Mr Paterson has held range of senior positions in multinational pharmaceutical companies. Throughout his career, he has been in charge for building and managing businesses throughout the world, including; mergers, integrations, acquisitions and restructures as President and CEO. From 2005 to 2013 he held senior positions at Merck Kgaa, including President of Europe, Canada and Australia. Prior to this, Mr Paterson was President of markets, President of Japan and Global Head of Cardiovascular Medicine. Between 1999 and 2005, Mr Paterson served at Roche Pharmaceuticals where he was recently Head of Pharmaceuticals in Roche's South Korean operation. He also served as Head of Commercial Operations for Roche China based in Shanghai. He served as Non-Executive Director of Cepheid Inc from April 2015 to November 2016.
Dr Wenyi Gu Non-Executive Director Oct 2018
Dr Gu currently works as a Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland where he began his postdoctoral work in 2001. Before engaging in nanomedicine, he worked on RNAibased gene therapy for years at Translational Research Institute. Dr Gu's research has been published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. He also held a Peter Doherty Fellowship (2006-2009) and was supported by the National Health and Medical Research Council to work at Harvard Medical School, Harvard University as a visiting fellow. He is a member of the Risk Management Committee.
Matthew Mcdonnell Chief Financial Officer
-
David St Denis Chief Operating Officer
-
Martha Engel General Counsel
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited A/C 2 650,345 9.90%
National Nominees Limited <Db A/C> 374,479 5.70%
HSBC Custody Nominees (Australia) Limited Gsco Eca 288,924 4.40%
Mercer Street Global Opportunity Fund LLC 280,000 4.26%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 260,807 3.97%
Mr Patrick Chew 176,460 2.69%
Citicorp Nominees Pty Limited 161,115 2.45%
HSBC Custody Nominees (Australia) Limited 150,030 2.28%
CS Fourth Nominees Pty Limited <Hsbc Cust Nom Au Ltd 11 A/C> 129,285 1.97%
Mr Daniel Bernard Clough 89,583 1.36%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 72,987 1.11%
Amedan Pty Ltd 65,340 0.99%
MDM Leby Hwang 59,000 0.90%
Through2 Investments Pty Ltd <Through2 Super Fund A/C> 48,000 0.73%
Sharepoint Solutions Pty Ltd 46,252 0.70%
J P Morgan Nominees Australia Pty Limited 45,476 0.69%
Mr Joseph John Doyle and Mrs Cheryl Anne Doyle 42,326 0.64%
Sean Barrett Pty Ltd <Super Fund A/C> 41,000 0.62%
Mr Donald Fletcher Cameron and Mrs Anne Cameron <Anne & Don Cameron S/F A/C> 40,000 0.61%
BNP Paribas Nominees Pty Ltd CIBC World Markets Inc <Drp> 30,459 0.46%

Profile

since

Note